Subcutaneous rozanolixizumab in pediatric patients with generalized myasthenia gravis: Clinical study design

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

Safety and efficacy with rozanolixizumab-noli in pediatric patients have not been established. Rozanolixizumab-noli is indicated by the US Food and Drug Administration for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.